BioAtla to Participate in the JMP Securities Life Sciences Conference
May 08, 2023 16:05 ET
|
BioAtla, Inc.
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023
May 04, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
March 23, 2023 16:05 ET
|
BioAtla, Inc.
- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS) cohort readout in 2H23 - Initiated the...
BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights
March 16, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces Change in Executive Leadership
February 27, 2023 08:07 ET
|
BioAtla, Inc.
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
February 23, 2023 08:00 ET
|
BioAtla, Inc.
Following the IND clearance, the Company is advancing into a Phase 1 clinical study Potentially addressing most common subtypes of adenocarcinoma including colon, lung, breast, pancreas, and prostate...
BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones
January 10, 2023 08:00 ET
|
BioAtla, Inc.
Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled BA3011...
BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 22, 2022 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Participate in the Jefferies London Healthcare Conference
November 08, 2022 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces $65 Million Underwritten Offering of its Common Stock
November 04, 2022 09:08 ET
|
BioAtla, Inc.
SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...